| scholarly article | Q13442814 |
| P356 | DOI | 10.1177/0269881116658987 |
| P698 | PubMed publication ID | 27443599 |
| P50 | author | Rodolfo Rossi | Q63364328 |
| Paolo Chiodini | Q37841178 | ||
| P2093 | author name string | Andrea de Bartolomeis | |
| Carmine Tomasetti | |||
| Felice Iasevoli | |||
| Elisabetta F Buonaguro | |||
| Federica Marmo | |||
| Gianmarco Latte | |||
| Livia Avvisati | |||
| P2860 | cites work | Glutamatergic drugs for schizophrenia: a systematic review and meta-analysis | Q22251177 |
| A novel mechanism of action of tetracyclines: effects on nitric oxide synthases | Q24680257 | ||
| Arc/Arg3.1 interacts with the endocytic machinery to regulate AMPA receptor trafficking | Q24681745 | ||
| A double-blind, randomized study of minocycline for the treatment of negative and cognitive symptoms in early-phase schizophrenia | Q28263942 | ||
| Minocycline benefits negative symptoms in early schizophrenia: a randomised double-blind placebo-controlled clinical trial in patients on standard treatment | Q28265163 | ||
| Minocycline add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study | Q28306923 | ||
| Minocycline supplementation for treatment of negative symptoms in early-phase schizophrenia: a double blind, randomized, controlled trial | Q28307393 | ||
| Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses | Q29618915 | ||
| Dysbindin-1 modulates prefrontal cortical activity and schizophrenia-like behaviors via dopamine/D2 pathways. | Q30465987 | ||
| Mice lacking the AMPA GluR1 receptor exhibit striatal hyperdopaminergia and 'schizophrenia-related' behaviors | Q42628411 | ||
| Functional neuroimaging of minocycline's effect in a patient with schizophrenia | Q43170176 | ||
| Minocycline inhibits cytochrome c release and delays progression of amyotrophic lateral sclerosis in mice | Q43977943 | ||
| Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis | Q44149270 | ||
| Homer 1a gene expression modulation by antipsychotic drugs: involvement of the glutamate metabotropic system and effects of D-cycloserine | Q44237544 | ||
| Method for quantitative in situ hybridization histochemistry and image analysis applied for Homer1a gene expression in rat brain | Q44501347 | ||
| Different effects of the NMDA receptor antagonists ketamine, MK-801, and memantine on postsynaptic density transcripts and their topography: role of Homer signaling, and implications for novel antipsychotic and pro-cognitive targets in psychosis | Q45283684 | ||
| Nitric oxide stimulates Ca(2+)-independent synaptic vesicle release. | Q46024772 | ||
| Evaluation of the pro-cognitive effects of the AMPA receptor positive modulator, 5-(1-piperidinylcarbonyl)-2,1,3-benzoxadiazole (CX691), in the rat. | Q46067102 | ||
| Dopamine receptor subtypes contribution to Homer1a induction: insights into antipsychotic molecular action | Q46109007 | ||
| Imaging brain gene expression profiles by antipsychotics: region-specific action of amisulpride on postsynaptic density transcripts compared to haloperidol | Q46219167 | ||
| Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study | Q46771704 | ||
| Neuroprotectant minocycline depresses glutamatergic neurotransmission and Ca(2+) signalling in hippocampal neurons. | Q46912355 | ||
| Homer splice variants modulation within cortico-subcortical regions by dopamine D2 antagonists, a partial agonist, and an indirect agonist: implication for glutamatergic postsynaptic density in antipsychotics action | Q46966416 | ||
| Improvement by minocycline of methamphetamine-induced impairment of recognition memory in mice | Q46971610 | ||
| Minocycline as add-on treatment decreases the negative symptoms of schizophrenia; a randomized placebo-controlled clinical trial | Q48184666 | ||
| Differential expression of Homer 1 gene by acute and chronic administration of antipsychotics and dopamine transporter inhibitors in the rat forebrain | Q48234714 | ||
| Transient neuroprotection by minocycline following traumatic brain injury is associated with attenuated microglial activation but no changes in cell apoptosis or neutrophil infiltration. | Q48328477 | ||
| Possible antipsychotic effects of minocycline in patients with schizophrenia | Q48400463 | ||
| Effects of minocycline add-on treatment on brain morphometry and cerebral perfusion in recent-onset schizophrenia | Q48416426 | ||
| Protective effects of minocycline on 3,4-methylenedioxymethamphetamine-induced neurotoxicity in serotonergic and dopaminergic neurons of mouse brain. | Q48465777 | ||
| Protective effects of minocycline on behavioral changes and neurotoxicity in mice after administration of methamphetamine. | Q48472593 | ||
| Neuroleptics increase c-fos expression in the forebrain: contrasting effects of haloperidol and clozapine | Q48594909 | ||
| Regulation of postsynaptic plasticity genes' expression and topography by sustained dopamine perturbation and modulation by acute memantine: relevance to schizophrenia | Q48659194 | ||
| Minocycline but not tigecycline is neuroprotective and reduces the neuroinflammatory response induced by the superimposition of sepsis upon traumatic brain injury | Q48785510 | ||
| The acute and chronic effects of combined antipsychotic-mood stabilizing treatment on the expression of cortical and striatal postsynaptic density genes | Q48967410 | ||
| Peroxynitrite inhibits glutamate transporter subtypes | Q49057961 | ||
| Promising use of minocycline augmentation with clozapine in treatment-resistant schizophrenia. | Q50653774 | ||
| Ketamine-induced NMDA receptor hypofunction as a model of memory impairment and psychosis. | Q51481467 | ||
| Nitric oxide inhibits 3H-glutamate transport in synaptosomes. | Q52271960 | ||
| Epidermal immunization by a needle-free powder delivery technology: Immunogenicity of influenza vaccine and protection in mice | Q56772848 | ||
| Tetracyclines | Q57533398 | ||
| Dysfunctional and compensatory prefrontal cortical systems, genes and the pathogenesis of schizophrenia | Q33295367 | ||
| De novo CNV analysis implicates specific abnormalities of postsynaptic signalling complexes in the pathogenesis of schizophrenia. | Q33398247 | ||
| Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia | Q33612679 | ||
| To model a psychiatric disorder in animals: schizophrenia as a reality test | Q33913794 | ||
| Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease | Q33952130 | ||
| Mouse models of genetic effects on cognition: relevance to schizophrenia | Q34183979 | ||
| Efficacy and tolerability of minocycline augmentation therapy in schizophrenia: a systematic review and meta-analysis of randomized controlled trials | Q34432085 | ||
| Homeostatic scaling requires group I mGluR activation mediated by Homer1a | Q34455735 | ||
| Arc-dependent synapse-specific homeostatic plasticity | Q34490539 | ||
| Protective effects of minocycline on the reduction of dopamine transporters in the striatum after administration of methamphetamine: a positron emission tomography study in conscious monkeys. | Q34567678 | ||
| Glutamate receptor dysfunction and schizophrenia | Q34719075 | ||
| Neuronal nitric oxide contributes to neuroplasticity-associated protein expression through cGMP, protein kinase G, and extracellular signal-regulated kinase | Q35033344 | ||
| Prospects for minocycline neuroprotection | Q35079515 | ||
| Gender differences and the effects of ketamine in healthy volunteers. | Q35883433 | ||
| Minocycline inhibits caspase-independent and -dependent mitochondrial cell death pathways in models of Huntington's disease | Q35918549 | ||
| Phosphorylation of AMPA receptors: mechanisms and synaptic plasticity | Q36356588 | ||
| Pharmacological treatment of primary negative symptoms in schizophrenia: a systematic review | Q36576234 | ||
| A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window | Q36678875 | ||
| Epileptiform stimulus increases Homer 1a expression to modulate synapse number and activity in hippocampal cultures | Q36700675 | ||
| Enhancement by interleukin-1β of AMPA and NMDA receptor-mediated currents in adult rat spinal superficial dorsal horn neurons | Q36755430 | ||
| Minocycline increases phosphorylation and membrane insertion of neuronal GluR1 receptors | Q37018365 | ||
| Modulation of behavior by scaffolding proteins of the post-synaptic density | Q37161173 | ||
| Neuroinflammation is associated with changes in glial mGluR5 expression and the development of neonatal excitotoxic lesions | Q37698259 | ||
| New views of Arc, a master regulator of synaptic plasticity | Q37833492 | ||
| Targeting glutamate system for novel antipsychotic approaches: relevance for residual psychotic symptoms and treatment resistant schizophrenia. | Q37990329 | ||
| Calcium-dependent networks in dopamine-glutamate interaction: the role of postsynaptic scaffolding proteins. | Q38024032 | ||
| Capturing the angel in "angel dust": twenty years of translational neuroscience studies of NMDA receptor antagonists in animals and humans | Q38035216 | ||
| Scaffolding proteins of the post-synaptic density contribute to synaptic plasticity by regulating receptor localization and distribution: relevance for neuropsychiatric diseases | Q38044699 | ||
| Intracellular pathways of antipsychotic combined therapies: implication for psychiatric disorders treatment. | Q38120101 | ||
| Molecular mechanisms of homeostatic synaptic downscaling | Q38126274 | ||
| The glutamatergic aspects of schizophrenia molecular pathophysiology: role of the postsynaptic density, and implications for treatment | Q38213709 | ||
| Minocycline, a second-generation tetracycline, as a neuroprotective agent in an animal model of schizophrenia | Q40214962 | ||
| P433 | issue | 4 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | schizophrenia | Q41112 |
| haloperidol | Q251347 | ||
| minocycline | Q415336 | ||
| P304 | page(s) | 406-417 | |
| P577 | publication date | 2016-07-19 | |
| P1433 | published in | Journal of Psychopharmacology | Q6295819 |
| P1476 | title | Postsynaptic density protein transcripts are differentially modulated by minocycline alone or in add-on to haloperidol: Implications for treatment resistant schizophrenia | |
| P478 | volume | 31 |
| Q47871481 | Immediate-Early Genes Modulation by Antipsychotics: Translational Implications for a Putative Gateway to Drug-Induced Long-Term Brain Changes. |
| Q38770806 | Treating the Synapse in Major Psychiatric Disorders: The Role of Postsynaptic Density Network in Dopamine-Glutamate Interplay and Psychopharmacologic Drugs Molecular Actions |
Search more.